Substituted 2,3-diphenyl pyridines
View Patent ↗Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
1. A compound of structural formula I:
or a pharmaceutically acceptable salt thereof, wherein;
R 1 is selected from:
(1) hydrogen,
(2) halogen,
(3) C 1-4 alkyl,
(4) cycloheteroalkyl,
(5) cycloheteroalkyl-C 1-4 alkyl,
(6) heteroaryl,
(7) aryl-C 1-4 alkyl,
(8) heteroaryl-C 1-4 alkyl;
(9) —OR d ,
(10) —SR d ,
(11) —O—(CR f R g ) n —NR d R e ,
(12) —O—(CR f R g ) n —NH—C(O)—R d ,
(13) —O—(CR f R g ) n —NH—S(O) p R d ,
(14) —O—(CR f R g ) n —NH—C(O)—NR d R e ,
(15) —O—(CR f R g ) n —C(O)—NR d R e ,
(16) —NR d R e ,
(17) —C(O)R d ,
(18) —CO 2 R d ,
(19) —CN,
(20) —C(O)NR d R e ,
(21) —NR e C(O)R d ,
(22) —NR e C(O)OR d ,
(23) —NR e C(O)NR d R e ,
wherein the alkyl groups are optionally substituted with one to four substituents independently selected from R a , and cycloheteroalkyl, aryl and heteroaryl are optionally substituted with one to four substituents independently selected from R b ;
R 2 is selected from:
(1) hydrogen,
(2) cyano,
(3) —C(O)OR d ,
(4) —C(O)NR d R e ,
(5) halogen,
(6) nitro,
(7) trifluoromethyl, and
(8) C(O)NH—NR d R e ;
provided that R 1 and R 2 are not both hydrogen;
R 3 is selected from:
(1) hydrogen,
(2) C 1-3 alkyl,
(3) cycloalkyl, and
(4) trifluoromethyl,
wherein alkyl, and cycloalkyl are optionally substituted with one to four substituents independently selected from R a ;
R 4 , R 5 , R 6 and R 7 are each independently selected from:
(1) hydrogen,
(2) halogen,
(3) amino,
(4) carboxy,
(5) C 1-4 alkyl,
(6)
(7) aryl,
(8) aryl C 1-4 alkyl,
(9) trifluoromethyl,
(10) —OC(O)C 1-4 alkyl, and
(11) —OC(O)NR d R e ,
provided that R 6 and R 7 are not both hydrogen;
each R a is independently selected from:
(1) —C(O)R d ,
(2) —CO 2 R d ,
(3) —CO 2 (CR f R g ) n CONR d R e ,
(4) —OC(O)R d ,
(5) —CN,
(6) —C(O)NR d R e ,
(7) —NR e C(O)R d ,
(8) —OC(O)NR d R e ,
(9) —NR e C(O)OR d ,
(10) —NR e C(O)NR d R e ,
(11) —CR d (N—OR d ),
(12) —CF 3 ,
(13) —OCF 3 , and
(14) C 3-8 cycloalkyl;
each R b is independently selected from:
(1) R a ,
(2) C 1-4 alkyl,
(3) C 2-4 alkenyl,
(4) C 2-4 alkynyl,
(5) aryl, and
(6) aryl-C 1-4 alkyl;
wherein alkyl, alkenyl, alkynyl, and aryl are optionally substituted with one to four substituents selected from a group independently selected from R c ;
each R c is independently selected from:
(1) halogen,
(2) amino,
(3) carboxy,
(4) —OR d ,
(5) —NR e S(O) m R d ,
(6) —NO 2 ,
(7) halogen,
(8) —S(O) m R d ,
(9) —SR d ,
(10) —S(O) 2 OR d ,
(11) —S(O) m NR d R e ,
(12) —NR d R e ,
(13) —O(CR f R g ) n NR d R e ,
(14) C 1-4 alkyl,
(15) C 1-4 alkoxy,
(16) aryl,
(12) aryl C 1-4 alkyl,
(13) hydroxy,
(14) CF 3 ,
(15) —OC(O)C 1-4 alkyl, and
(16) —OC(O)NR d R e ;
R d and R a are independently selected from:
(1) hydrogen,
(2) C 1-10 alkyl, unsubstituted or substituted with one to three substituents selected from R h ,
(3) C 2-10 alkenyl;
(4) C 2-10 alkynyl;
(5) cycloalkyl, unsubstituted or substituted with one to three substituents selected from R h ;
(6) cycloalkyl-C 1-4 alkyl;
(7) cycloheteroalkyl, unsubstituted or substituted with one to three substituents selected from R h ;
(8) cycloheteroalkyl-C 1-4 alkyl, unsubstituted or substituted with an R h substituent;
(9) aryl, unsubstituted or substituted with one to three substituents selected from R h ;
(10) heteroaryl, unsubstituted or substituted with one to three substituents selected from R h ;
(11) aryl-C 1-4 alkyl, unsubstituted or substituted with one to three substituents selected from R h ; and
(12) heteroaryl-C 1-4 alkyl, unsubstituted or substituted with one to three substituents selected from R h ; or
R d and R e together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N—R h , unsubstituted or substituted with one or two oxo groups;
R f and R g are independently selected from
(1) hydrogen, and
(2) C 1-4 alkyl;
each R h is independently selected from:
(1) halogen,
(2) amino,
(3) hydroxycarbonyl,
(4) C 1-4 alkyl,
(5) C 1-4 alkoxy,
(6) aryl,
(7) aryl C 1-4 alkyl,
(8) hydroxy,
(9) —CF 3 ,
(10) —OC(O)C 1-4 alkyl,
(11) aryloxy,
(12) C 1-4 alkyloxycarbonyl-,
(13) —C(O)—NH—C 1-4 alkyl;
m is selected from 1 and 2;
n is selected from 1, 2, 3 and 4;
p is selected from 0, 1, and 2; and
and pharmaceutically acceptable salts thereof.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein:
R 1 is selected from:
(1) hydrogen,
(2) halogen,
(3) C 1-4 alkyl,
(4) cycloheteroalkyl,
(5) cycloheteroalkyl-C 1-4 alkyl,
(6) heteroaryl,
(7) aryl-C 1-4 alkyl,
(8) heteroaryl-C 1-4 alkyl;
(9) —OR d ,
(10) —SR d ,
(11) —O—(CR f R g ) n —NR d R e ,
(12) —O—(CR f R g ) n —NH—C(O)—R d ,
(13) —O—(CR f R g ) n —NH—S(O) p R d ,
(14) —O—(CR f R g ) n —NH—C(O)—NR d R e ,
(15) —O—(CR f R g ) n —C(O)—NR d R e ,
(16) —NR d R e ,
(17) —CO 2 H,
(18) —C(O)NR d R e ,
(19) —NR e C(O)R d ,
(20) —NR e C(O)OR d ,
(21) —NR e C(O)NR d R e ,
wherein the alkyl groups are optionally substituted with one to four substituents independently selected from R a , and cycloheteroalkyl, aryl and heteroaryl are optionally substituted with one to four substituents independently selected from R b ;
R 2 is selected from:
(1) hydrogen,
(2) cyano,
(3) —C(O)OR d ,
(4) —C(O)NR d R e ,
(5) halogen,
(6) nitro, and
(7) C(O)NH—NR d R e ;
provided that R 1 and R 2 are not both hydrogen;
R 3 is selected from:
(1) hydrogen,
(2) C 1-3 alkyl,
(3) cyclopropyl,
(4) trifluoromethyl,
wherein alkyl and cyclopropyl are optionally substituted with a substituent independently selected from R a ;
R 4 , R 5 , R 6 and R 7 are each independently selected from:
(1) hydrogen,
(2) halogen,
(3) amino,
(4) carboxy,
(5) C 1-4 alkyl,
(7) aryl,
(8) aryl C 1-4 alkyl,
(9) trifluoromethyl,
(10) —OC(O)C 1-4 alkyl, and
(11) —OC(O)NR d R e ,
provided that R 6 and R 7 are not both hydrogen;
each R a is independently selected from:
(1) —OR d ,
(2) —NR e S(O) m R d ,
(3) —NO 2 ,
(4) halogen,
(5) —S(O) m R d ,
(6) —SR d ,
(7) —S(O) 2 OR d ,
(8) —S(O) m NR d R e ,
(9) —NR d R e ,
(10) —O(CR f R g ) n NR d R e ,
(11) —C(O)R d ,
(12) —CO 2 R d ,
(13) —CO 2 (CR f R g ) n CONR d R e ,
(14) —OC(O)R d ,
(15) —CN,
(16) —C(O)NR d R e ,
(17) —NR e C(O)R d ,
(18) —OC(O)NR d R e ,
(19) —NR e C(O)OR d ,
(20) —NR e C(O)NR d R e ,
(21) —CR d (N—OR d ),
(22) —CF 3 ,
(23) —OCF 3 , and
(24) C 3-8 cycloalkyl;
each R b is independently selected from:
(1) R a ,
(2) C 1-4 alkyl,
(3) aryl, and
(4) aryl-C 1-4 alkyl;
wherein alkyl and aryl are optionally substituted with one to four substituents selected from a group independently selected from R c ;
each R c is independently selected from:
(1) halogen,
(2) amino,
(3) carboxy,
(4) C 1-4 alkyl,
(5) C 1-4 alkoxy,
(6) aryl,
(7) aryl C 1-4 alkyl,
(8) hydroxy,
(9) —CF 3 ,
(10) —OC(O)C 1-4 alkyl, and
(11) —OC(O)NR d R e ;
R d and R e are independently selected from:
(1) hydrogen,
(2) C 1-10 alkyl, unsubstituted or substituted with one to three substituents selected from R h ,
(3) C 2-10 alkenyl;
(4) C 2-10 alkynyl;
(5) cycloalkyl, unsubstituted or substituted with one to three substituents selected from R h ;
(6) cycloalkyl-C 1-4 alkyl-;
(7) cycloheteroalkyl, unsubstituted or substituted with one to three substituents selected from R h ;
(8) cycloheteroalkyl-C 1-4 alkyl- unsubstituted or substituted with an R h substituent;
(9) aryl, unsubstituted or substituted with one to three substituents selected from R h ;
(10) heteroaryl, unsubstituted or substituted with one to three substituents selected from R h ;
(11) aryl-C 1-4 alkyl-, unsubstituted or substituted with one to three substituents selected from R h ; and
(12) heteroaryl-C 1-4 alkyl-, unsubstituted or substituted with one to three substituents selected from R h ; or
R d and R e together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N—R h , unsubstituted or substituted with one or two oxo groups;
R f and R g are independently selected from
(1) hydrogen, and
(2) C 1-4 alkyl;
each R h is independently selected from:
(1) halogen,
(2) amino,
(3) hydroxycarbonyl,
(4) C 1-4 alkyl,
(5) C 1-4 alkoxy,
(6) aryl,
(7) aryl C 1-4 alkyl,
(8) hydroxy,
(9) trifluoromethyl,
(10) —OC(O)C 1-4 alkyl,
(11) aryloxy-,
(12) C 1-4 alkyloxycarbonyl-, and
(13) —C(O)—NH—C 1-4 alkyl;
m is selected from 1 and 2;
n is selected from 1, 2, and 3;
p is selected from 0, 1, and 2; and
and pharmaceutically acceptable salts thereof.
3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein:
R 1 is selected from:
(1) hydrogen,
(2) halogen,
(3) C 1-4 alkyl,
(4) cycloheteroalkyl,
(5) heteroaryl,
(6) aryl-C 1-4 alkyl,
(7) heteroaryl-C 1-4 alkyl;
(8) —OR d ,
(9) —SR d ,
(10) —O—(CH 2 ) n —NR d R e ,
(11) —O—(CH 2 ) n —NH—C(O)—R d ,
(12) —O—(CH 2 ) n —NH—S(O) p R d ,
(13) —O—(CH 2 ) n —NH—C(O)—NR d R e ,
(14) —O—(CH 2 ) n —C(O)—NR d R e ,
(15) —NR d R e , wherein R e is hydrogen,
(16) —CO 2 H,
(17) —C(O)NR d R e ,
(18) —NHC(O)R d ,
(19) —NHC(O)OR d ,
(20) —NHC(O)NR d R e ,
wherein the alkyl groups are optionally substituted with one to three substituents independently selected from R a , and cycloheteroalkyl, aryl and heteroaryl are optionally substituted with one to three substituents independently selected from R b ;
R 2 is selected from:
(1) hydrogen,
(2) cyano,
(3) —C(O)OH,
(4) —C(O)OCH 3 ,
(5) —C(O)NR d R e ,
(6) halogen,
(7) nitro, and
(8) C(O)NH—NR d R e , wherein R e is hydrogen;
provided that R 1 and R 2 are not both hydrogen;
R 3 is selected from:
(1) hydrogen, and
(2) methyl;
R 4 , R 5 , R 6 and R 7 are each independently selected from:
(1) hydrogen,
(2) halogen,
(3) amino,
(4) carboxy,
(5) C 1-4 alkyl,
(7) aryl,
(8) aryl C 1-4 alkyl,
(9) trifluoromethyl,
(10) —OC(O)C 1-4 alkyl, and
(11) —OC(O)NR d R e ,
provided that R 6 and R 7 are not both hydrogen;
each R a is independently selected from:
(1) —OR d ,
(2) —NR e S(O) m R d ,
(3) —NO 2 ,
(4) halogen,
(5) —S(O) m R d ,
(6) —SR d ,
(7) —S(O) 2 OR d ,
(8) —S(O) m NR d R e ,
(9) —NR d R e ,
(10) —O(CR f R g ) n —NR d R e ,
(11) —O-(CH 2 ) n —NH—C(O)—R d ,
(12) —CO 2 R d ,
(13) —CO 2 (CR f R g ) n CONR d R e ,
(14) —OC(O)R d ,
(15) —CN,
(16) —C(O)NR d R e ,
(17) —NR e C(O)R d ,
(18) —OC(O)NR d R e ,
(19) —NR e C(O)OR d ,
(20) —NR e C(O)NR d R e ,
(21) —CR d (N—OR d ),
(22) —CF 3 ,
(23) —OCF 3 , and
(24) C 3-8 cycloalkyl;
each R b is independently selected from:
(1) R a ,
(2) C 1-4 alkyl,
(3) aryl, and
(4) aryl-C 1-4 alkyl;
wherein alkyl and aryl are optionally substituted with one to three substituents selected from a group independently selected from R c ;
each R c is independently selected from:
(1) halogen,
(2) amino,
(3) carboxy,
(4) C 1-4 alkyl,
(5) C 1-4 alkoxy,
(6) aryl,
(7) aryl C 1-4 alkyl,
(8) hydroxy,
(9) —CF 3 ,
(10) —OC(O)C 1-4 alkyl, and
(11) —OC(O)NR d R e ;
R d is selected from:
(1) hydrogen,
(2) C 1-10 alkyl, unsubstituted or substituted with one to three substituents selected from R h ,
(3) C 2-4 alkenyl;
(4) cycloalkyl, unsubstituted or substituted with one to three substituents selected from R h ;
(5) cycloalkyl-C 1-4 alkyl;
(6) cycloheteroalkyl, unsubstituted or substituted with one to three substituents selected from R h ;
(7) cycloheteroalkyl-C 1-4 alkyl, unsubstituted or substituted with an Rh substituent;
(8) aryl, unsubstituted or substituted with one to three substituents selected from R h ;
(9) heteroaryl, unsubstituted or substituted with one to three substituents selected from R h ;
(10) aryl-C 1-4 alkyl, unsubstituted or substituted with one to three substituents selected from R h ; and
(11) heteroaryl-C 1-4 alkyl, unsubstituted or substituted with one to three substituents selected from R h ;
R e is hydrogen, or
R d and R e together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N—R h , unsubstituted or substituted with one or two oxo groups;
R f and R g are independently selected from
(1) hydrogen, and
(2) methyl;
each R h is independently selected from:
(1) halogen,
(2) amino,
(3) hydroxycarbonyl,
(4) C 1-4 alkyl,
(5) C 1-4 alkoxy,
(6) aryl,
(7) aryl C 1-4 alkyl,
(8) hydroxy,
(9) trifluoromethyl,
(10) —OC(O)C 1-4 alkyl,
(11) aryloxy-,
(12) C 1-4 alkyloxycarbonyl-, and
(13) —C(O)—NH—C 1-4 alkyl;
m is selected from 1 and 2;
n is selected from 1, 2, and 3;
p is selected from 0, 1, and 2; and
and pharmaceutically acceptable salts thereof.
4. The compound according to claim 1 , selected from:
(1) methyl 2-(benzyloxy)-6-(4-chlorophenyl)-5-(phenyl)pyridine-3-carboxylate;
(2) methyl 2-(allyloxy)-6-(4-chlorophenyl)-5-(phenyl)pyridine-3-carboxylate;
(3) 2-(benzyloxy)-6-(4-chlorophenyl)-5-(phenyl)pyridine-3-nitrile;
(4) 2-(methoxy)-6-(4-chlorophenyl)-5-(phenyl)pyridine-3-nitrile; methyl 2-(methoxy)-6-(4-chlorophenyl)-5-(phenyl)pyridine-3-carboxylate;
(6) methyl 2-(methoxy)-6-(4-chlorophenyl)-5-(phenyl)pyridine-3-carboxylate;
(7) N-(piperidin-1-yl)-2-(methoxy)-6-(4-chlorophenyl)-5-(phenyl)pyridine-3-carboxamide;
(8) 2-(methoxy)-6-(4-chlorophenyl)-5-(phenyl)-3-(piperidin-1-ylcarbonyl)pyridine;
(9) N-(morpholin-4-yl)-2-(methoxy)-6-(4-chlorophenyl)-5-(phenyl)pyridine-3-carboxamide;
(10) N-(t-butyl)-2-(methoxy)-6-(4-chlorophenyl)-5-(phenyl)pyridine-3-carboxamide;
(11) N-(cyclopentyl)-2-(methoxy)-6-(4-chlorophenyl)-5-(phenyl)pyridine-3-carboxamide;
(12) N-(phenyl)-2-(methoxy)-6-(4-chlorophenyl)-5-(phenyl)pyridine-3-carboxamide;
(13) N-(cyclohexyl)-2-(benzyloxy)-6-(4-chlorophenyl)-5-(phenyl)pyridine-3-carboxamide;
(14) N-benzyl-2-(benzyloxy)-6-(4-chlorophenyl)-5-(phenyl)pyridine-3-carboxamide;
(15) N-(n-pentyl)-2-(benzyloxy)-6-(4-chlorophenyl)-5-(phenyl)pyridine-3-carboxamide;
(16) N-(t-butyl)-2-(benzyloxy)-6-(4-chlorophenyl)-5-(phenyl)pyridine-3-carboxamide;
(17) N-(piperidin-1-yl)-2-(benzyloxy)-6-(4-chlorophenyl)-5-(phenyl)pyridine-3-carboxamide;
(18) N,N-dimethyl-2-(benzyloxy)-6-(4-chlorophenyl)-5-(phenyl)pyridine-3-carboxamide;
(19) N-methyl-2-(benzyloxy)-6-(4-chlorophenyl)-5-(phenyl)pyridine-3-carboxamide;
(20) 2-(benzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-nitrile;
(21) 2-(4-fluorobenzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-nitrile;
(22) 2-(2,4-difluorobenzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-nitrile;
(23) 2-(3,4-difluorobenzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-nitrile;
(24) 2-(3,5-difluorobenzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-nitrile;
(25) 2-(4-trifluoromethylbenzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-nitrile;
(26) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]nicotinonitrile;
(27) 2-(2-aminoethoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)nicotinonitrile;
(28) N-(2-{[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]oxy}ethyl)benzamide;
(29) N-(2-{[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]oxy}ethyl)-4-fluorobenzamide;
(30) N-(2-{[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]oxy}ethyl)cyclopentanecarboxamide;
(31) N-(2-{[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]oxy}ethyl)cyclobutanecarboxamide;
(32) N-(2-{[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]oxy}ethyl)cyclopropanecarboxamide;
(33) 2-chloro-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-N-piperidin-1-ylnicotinamide;
(34) N-(n-hexyl)-2-(chloro)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(35) N-(n-propyl)-2-(chloro)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(36) N-N-(dimethyl)-2-(chloro)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(37) 2-chloro-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)nicotinonitrile;
(38) 2-[(3-chlorobenzyl)oxy]-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl) nicotinonitrile;
(39) 5-(4-chlorophenyl)-2-(cyclohexyloxy)-6-(2,4-dichlorophenyl)nicotinonitrile;
(40) 5-(4-chlorophenyl)-2-[(5-chloropyridin-3-yl)oxy]-6-(2,4-dichlorophenyl)-nicotinonitrile;
(41) 5-(4-chlorophenyl)-2-(3,5-dichlorophenoxy)-6-(2,4-dichlorophenyl) nicotinonitrile;
(42) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(pyridin-3-yloxy)nicotinonitrile;
(43) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(4-methoxyphenoxy)nicotinonitrile;
(44) 2-(3-chlorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl) nicotinonitrile;
(45) 2-(4-chlorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)nicotinonitrile;
(46) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(4-fluorophenoxy)nicotinonitrile;
(47) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3-fluorophenoxy)nicotinonitrile;
(48) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy) nicotinonitrile;
(49) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[1-(4-fluorophenyl)ethoxy]-nicotinonitrile;
(50) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(4-fluorophenyl)thio] nicotinonitrile;
(51) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorobenzyl) nicotinonitrile,
(52) methyl2-(benzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxylate;
(53) N-(piperidin-1-yl)-2-(benzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(54) 2-(benzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-3-(piperidinocarbonyl)pyridine;
(55) N-(n-pentyl)-2-(benzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl) pyridine-3-carboxamide;
(56) N-(n-propyl)-2-(benzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl) pyridine-3-carboxamide;
(57) N-(methyl)-2-(benzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(58) N-N-(dimethyl)-2-(benzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl) pyridine-3-carboxamide;
(59) N-(ethyl)-2-(benzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(60) N-(n-butyl)-2-(benzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(61) N-(cyclopentyl)-2-(benzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl) pyridine-3-carboxamide;
(62) 2-(benzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(63) methyl 6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxylate;
(64) N-(piperidin-1-yl)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(65) 6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-3-(piperidinocarbonyl)pyridine;
(66) N-(cyclohexyl)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(67) N-(n-hexyl)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(68) methyl 2-(n-butoxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxylate;
(69) methyl 2-(n-pentoxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxylate;
(70) methyl2-(cyclopropylmethoxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxylate;
(71) methyl 2-(cyclohexylmethoxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl) pyridine-3-carboxylate;
(72) methyl 2-(2-ethoxyethoxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl) pyridine-3-carboxylate;
(73) N-methyl-2-(cyclohexylmethoxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(74) N-(n-propyl)-2-(cyclohexylmethoxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(75) 2-(n-butoxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(76) N-methyl-2-(n-butoxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(77) N-(n-propyl)-2-(n-butoxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(78) N-cyclopentyl-2-(n-butoxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl) pyridine-3-carboxamide;
(79) methyl 2-(3,4-difluorobenzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxylate;
(80) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorobenzyl)oxy] nicotinic acid;
(81) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorobenzyl)oxy]-N-methylnicotinamide;
(82) N-(ethyl)-2-(3,4-difluorobenzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(83) N-(n-propyl)-2-(3,4-difluorobenzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(84) N-(2-fluoroethyl)-2-(3,4-difluorobenzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(85) N-(i-propyl)-2-(3,4-difluorobenzyloxy)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carboxamide;
(86) methyl 2-chloro-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)nicotinate;
(87) methyl 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)nicotinate;
(88) methyl 5-(4-chlorophenyl)-2-[(5-chloropyridin-3-yl)oxy]-6-(2,4-dichlorophenyl)nicotinate;
(89) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)nicotinic acid;
(90) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-N-ethylnicotinamide;
(91) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-N-methylnicotinamide;
(92) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-N′,N′-dimethylnicotinohydrazide;
(93) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-N-pyrrolidin-1-ylnicotinamide;
(94) 5-(4-chlorophenyl)-N-cyclohexyl-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)nicotinamide;
(95) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy) nicotinamide;
(96) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-N-isopropylnicotinamide;
(97) 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-6-[(3,4-difluorobenzyl)oxy] pyridine;
(98) methyl 6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-2-carboxylate;
(99) N-(cyclohexyl)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-2-carboxamide;
(100) N-(piperidin-1-yl)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-2-carboxamide;
(101) 6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-(piperidinyl-1-carbonyl)pyridine;
(102) N-(n-hexyl)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-2-carboxamide;
(103) N-(cyclopentyl)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-2-carboxamide;
(104) N-(cycloheptyl)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-2-carboxamide;
(105) N-(heptyl)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-2-carboxamide;
(106) N-(benzyl)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-2-carboxamide;
(107) N-(phenyl)-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-2-carboxamide;
(108) methyl 6-(2,4-dichlorophenyl)-2-[(3,4-difluorobenzyl)oxy]-5-(4-fluorophenyl)nicotinate;
(109) 6-(2,4-dichlorophenyl)-2-[(3,4-difluorobenzyl)oxy]-5-(4-fluorophenyl) nicotinic acid;
(110) 6-(2,4-dichlorophenyl)-2-[(3,4-difluorobenzyl)oxy]-5-(4-fluorophenyl)-N-methylnicotinamide;
(111) 2-[(3-chlorobenzyl)oxy]-6-(2,4-dichlorophenyl)-5-(4-fluorophenyl) nicotinonitrile;
(112) 6-(2,4-dichlorophenyl)-2-[(3,4-difluorobenzyl)oxy]-5-(4-fluorophenyl) nicotinonitrile;
(113) 6-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-2-(pyridin-3-ylmethoxy) nicotinonitrile;
(114) 2-[(4-chlorobenzyl)oxy]-6-(2,4-dichlorophenyl)-5-(4-fluorophenyl) nicotinonitrile;
(115) 2-[(6-chloropyridin-3-yl)methoxy]-6-(2,4-dichlorophenyl)-5-(4-fluorophenyl) nicotinonitrile;
(116) methyl 2-chloro-6-(2,4-dichlorophenyl)-5-(4-fluorophenyl)nicotinate;
(117) methyl 6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-5-(4-fluorophenyl) nicotinate;
(118) 2-chloro-6-(2,4-dichlorophenyl)-5-(4-methylphenyl)nicotinonitrile;
(119) 6-(2,4-dichlorophenyl)-5-(4-methylphenyl)-2-(1-(4-fluorophenyl)ethoxy)nicotinonitrile;
(120) 6-(2,4-dichlorophenyl)-2-[2-(diethylamino)ethoxy]-5-(4-methylphenyl) nicotinonitrile;
(121) 6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-5-(4-methylphenyl) nicotinonitrile;
(122) 2-(cyclohexylmethoxy)-6-(2,4-dichlorophenyl)-5-(4-methylphenyl) nicotinonitrile;
(123) 2-butoxy-6-(2,4-dichlorophenyl)-5-(4-methylphenyl)nicotinonitrile;
(124) 6-(2,4-dichlorophenyl)-2-[(3,4-difluorobenzyl)oxy]-5-(4-methylphenyl)-nicotinonitrile;
(125) methyl 4-({[3-cyano-6-(2,4-dichlorophenyl)-5-(4-methylphenyl)pyridin-2-yl]oxy}methyl)benzoate;
(126) 4-({[3-cyano-6-(2,4-dichlorophenyl)-5-(4-methylphenyl)pyridin-2-yl]oxy}methyl)benzoic acid;
(127) 4-({[3-cyano-6-(2,4-dichlorophenyl)-5-(4-methylphenyl)pyridin-2-yl]oxy}methyl)-N-methylbenzamide;
(128) 6-(2,4-dichlorophenyl)-5-(4-methylphenyl)-2-piperidin-1-ylnicotinonitrile;
(129) 2-(cyclohexylamino)-6-(2,4-dichlorophenyl)-5-(4-methylphenyl) nicotinonitrile;
(130) 6-(2,4-dichlorophenyl)-5-(4-methylphenyl)-2-(4-methylpiperazin-1-yl) nicotinonitrile;
(131) 6-(2,4-dichlorophenyl)-2-[(3,4-difluorobenzyl)amino]-5-(4-methylphenyl)-nicotinonitrile;
(132) 6-(2,4-dichlorophenyl)-5-(4-methylphenyl)-2-pyrrolidin-1-ylnicotinonitrile;
(133) 6-(2-chlorophenyl)-5-(4-chlorophenyl)-2-[(3,4-difluorobenzyl)oxy] nicotinonitrile;
(134) 6-(2-chlorophenyl)-5-(4-chlorophenyl)-2-[(3,4-difluorobenzyl)oxy] nicotinamide;
(135) 2-chloro-6-(2-chlorophenyl)-5-(4-chlorophenyl)nicotinonitrile;
(136) 6-(2-chlorophenyl)-5-(4-chlorophenyl)-2-[(5-chloropyridin-3-yl)oxy] nicotinonitrile;
(137) 6-(2-chlorophenyl)-5-(4-chlorophenyl)-2-(3,4-difluorophenoxy)nicotinonitrile;
(138) 6-(2-chlorophenyl)-5-(4-chlorophenyl)-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]nicotinonitrile;
(139) 2-(2-aminoethoxy)-6-(2-chlorophenyl)-5-(4-chlorophenyl)nicotinonitrile;
(140) N-(2-{[6-(2-chlorophenyl)-5-(4-chlorophenyl)-3-cyanopyridin-2-yl]oxy}ethyl)benzenesulfonamide;
(141) N-(2-{[6-(2-chlorophenyl)-5-(4-chlorophenyl)-3-cyanopyridin-2-yl]oxy}ethyl)acetamide;
(142) N-(2-{[6-(2-chlorophenyl)-5-(4-chlorophenyl)-3-cyanopyridin-2-yl]oxy}ethyl)cyclopropanecarboxamide;
(143) N-(2-{[6-(2-chlorophenyl)-5-(4-chlorophenyl)-3-cyanopyridin-2-yl]oxy}ethyl)benzamide;
(144) N-(2-{[6-(2-chlorophenyl)-5-(4-chlorophenyl)-3-cyanopyridin-2-yl]oxy}ethyl)methanesulfonamide;
(145) N′-(2-{[6-(2-chlorophenyl)-5-(4-chlorophenyl)-3-cyanopyridin-2-yl]oxy} ethyl)-N,N-dimethylurea;
(146) N-(2-{[6-(2-chlorophenyl)-5-(4-chlorophenyl)-3-cyanopyridin-2-yl]oxy}ethyl)morpholine-4-carboxamide;
and pharmaceutically acceptable salts thereof.
5. The compound according to claim 1 of structural formula II:
wherein: R 1 is selected from:
(1) hydrogen,
(2) halogen,
(3) C 1-4 alkyl,
(4) cycloheteroalkyl,
(5) cycloheteroalkyl-C 1-4 alkyl,
(6) heteroaryl,
(7) aryl-C 1-4 alkyl,
(8) heteroaryl-C 1-4 alkyl;
(9) —OR d ,
(10) —SR d ,
(11) —O—(CR f R g ) n —NR d R e ,
(12) —O—(CR f R g ) n —NH—C(O)—R d ,
(13) —O—(CR f R g ) n —NH—S(O) p R d ,
(14) —O—(CR f R g ) n —NH—C(O)—NR d R e ,
(15) —O—(CR f R g ) n —C(O)—NR d R e ,
(16) —NR d R e ,
(17) —CO 2 H,
(18) —C(O)NR d R e ,
(19) —NR e C(O)R d ,
(20) —NR e C(O)OR d ,
(21) —NR e C(O)NR d R e ,
wherein the alkyl groups are optionally substituted with one to four substituents independently selected from R a , and cycloheteroalkyl, aryl and heteroaryl are optionally substituted with one to four substituents independently selected from R b ;
R 2 is selected from:
(1) hydrogen,
(2) cyano,
(3) —C(O)OR d ,
(4) —C(O)NR d R e ,
(5) halogen,
(6) nitro, and
(7) C(O)NH—NR d R e ;
provided that R 1 and R 2 are not both hydrogen;
R 4 , R 6 and R 7 are each independently selected from:
(1) hydrogen,
(2) halogen,
(3) amino,
(4) carboxy,
(5) C 1-4 alkyl,
(7) aryl,
(8) aryl C 1-4 alkyl,
(9) trifluoromethyl,
(10) —OC(O)C 1-4 alkyl, and
(11) —OC(O)NR d R e ,
provided that R 6 and R 7 are not both hydrogen;
each R a is independently selected from:
(1) —OR d ,
(2) —NR e S(O) m R d ,
(3) —NO 2 ,
(4) halogen,
(5) —S(O) m R d ,
(6) —SR d ,
(7) —S(O) 2 OR d ,
(8) —S(O) m NR d R e ,
(9) —NR d R e ,
(10) —O(CR f R g ) n NR d R e ,
(11) —C(O)R d ,
(12) —CO 2 R d ,
(13) —CO 2 (CR f R g ) n CONR d R e ,
(14) —OC(O)R d ,
(15) —CN,
(16) —C(O)NR d R e ,
(17) —NR e C(O)R d ,
(18) —OC(O)NR d R e ,
(19) —NR e C(O)OR d ,
(20) —NR e C(O)NR d R e ,
(21) —CR d (N—OR d ),
(22) —CF 3 ,
(23) —OCF 3 , and
(24) C 3-8 cycloalkyl;
each R b is independently selected from:
(1) R a ,
(2) C 1-4 alkyl,
(3) aryl, and
(4) aryl-C 1-4 alkyl;
wherein alkyl and aryl are optionally substituted with one to four substituents selected from a group independently selected from R c ;
each R c is independently selected from:
(1) halogen,
(2) amino,
(3) carboxy,
(4) C 1-4 alkyl,
(5) C 1-4 alkoxy,
(6) aryl,
(7) aryl C 1-4 alkyl,
(8) hydroxy,
(9) CF 3 ,
(10) —OC(O)C 1-4 alkyl, and
(11) —OC(O)NR d R e ;
R d and R e are independently selected from:
(1) hydrogen,
(2) C 1-10 alkyl, unsubstituted or substituted with one to three substituents selected from R h ,
(3) C 2-10 alkenyl;
(4) C 2-10 alkynyl;
(5) cycloalkyl, unsubstituted or substituted with one to three substituents selected from R h ;
(6) cycloalkyl-C 1-4 alkyl-;
(7) cycloheteroalkyl, unsubstituted or substituted with one to three substituents selected from R h ;
(8) cycloheteroalkyl-C 1-4 alkyl-, unsubtituted or substituted with an Rh substituent;
(9) aryl, unsubstituted or substituted with one to three substituents selected from R h ;
(10) heteroaryl, unsubstituted or substituted with one to three substituents selected from R h ;
(11) aryl-C 1-4 alkyl-, unsubstituted or substituted with one to three substituents selected from R h ; and
(12) heteroaryl-C 1-4 alkyl-, unsubstituted or substituted with one to three substituents selected from R h ; or
R d and R e together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0 to 2 additional heteroatoms independently selected from oxygen, sulfur and N—R h , unsubstituted or substituted with one or two oxo groups;
R f and R g are independently selected from
(1) hydrogen, and
(2) C 1-4 alkyl;
each R h is independently selected from:
(1) halogen,
(2) amino,
(3) hydroxycarbonyl,
(4) C 1-4 alkyl,
(5) C 1-4 alkoxy,
(6) aryl,
(7) aryl C 1-4 alkyl,
(8) hydroxy,
(9) trifluoromethyl,
(10) —OC(O)C 1-4 alkyl,
(11) aryloxy-,
(12) C1-4alkyloxycarbonyl-, and
(13) —C(O)—NH—C 1-4 alkyl;
m is selected from 1 and 2;
n is selected from 1, 2, and 3;
p is selected from 0, 1, and 2; and
and pharmaceutically acceptable salts thereof.
6. The compound according to claim 5 , wherein:
R 1 is selected from:
(1) hydrogen,
(2) halogen,
(3) C 1-4 alkyl,
(4) cycloheteroalkyl,
(5) heteroaryl,
(6) aryl-C 1-4 alkyl,
(7) heteroaryl-C 1-4 alkyl;
(8) —OR d ,
(9) —SR d ,
(10) —O—(CH 2 ) n —NR d R e ,
(11) —O—(CH 2 ) n —NH—C(O)—R d ,
(12) —O—(CH 2 ) n —NH—S(O) p R d ,
(13) —O—(CH 2 ) n —NH—C(O)—NR d R e ,
(14) —O—(CH 2 ) n —C(O)—NR d R e ,
(15) —NR d R e , wherein R e is hydrogen,
(16) —CO 2 H,
(17) —C(O)NR d R e ,
(18) —NHC(O)R d ,
(19) —NHC(O)OR d ,
(20) —NHC(O)NR d R e ,
wherein the alkyl groups are optionally substituted with one to three substituents independently selected from R a , and cycloheteroalkyl, aryl and heteroaryl are optionally substituted with one to three substituents independently selected from R b ;
R 2 is selected from:
(1) hydrogen,
(2) cyano,
(3) —C(O)OH,
(4) —C(O)OCH 3 ,
(5) —C(O)NR d R e ,
(6) halogen,
(7) nitro, and
(8) C(O)NH—NR d R e , wherein R e is hydrogen;
provided that R 1 and R 2 are not both hydrogen;
R 4 , R 6 and R 7 are each independently selected from:
(1) hydrogen,
(2) halogen,
(3) amino,
(4) carboxy,
(5) C 1-4 alkyl,
(7) aryl,
(8) benzyl,
(9) trifluoromethyl,
(10) —OC(O)C 1-4 alkyl, and
(11) —OC(O)NR d R e ,
provided that R 6 and R 7 are not both hydrogen;
each R a is independently selected from:
(1) —OR d ,
(2) —NR e S(O) m R d ,
(3) —NO 2 ,
(4) halogen,
(5) —S(O) m R d ,
(6) —SR d ,
(7) —S(O) 2 OR d ,
(8) —S(O) m NR d R e ,
(9) —NR d R e ,
(10) —O(CR f R g ) n NR d R e ,
(11) —(O)R d ,
(12) —CO 2 R d ,
(13) —CO 2 (CR f R g ) n CONR d R e ,
(14) —OC(O)R d ,
(15) —CN,
(16) —C(O)NR d R e ,
(17) —NR e C(O)R d ,
(18) —OC(O)NR d R e ,
(19) —NR e C(O)OR d ,
(20) —NR e C(O)NR d R e ,
(21) —CR d (N—OR d ),
(22) —CF 3 ,
(23) —OCF 3 , and
(24) C 3-8 cycloalkyl;
each R b is independently selected from:
(1) R a ,
(2) C 1-4 alkyl,
(3) aryl, and
(4) aryl-C 1-4 alkyl
wherein alkyl and aryl are optionally substituted with one to three substituents selected from a group independently selected from R c ;
each R c is independently selected from:
(1) halogen,
(2) amino,
(3) carboxy,
(4) C 1-4 alkyl,
(5) C 1-4 alkoxy,
(6) aryl,
(7) aryl C 1-4 alkyl,
(8) hydroxy,
(9) CF 3 ,
(10) —OC(O)C 1-4 alkyl, and
(11) —OC(O)NR d R e ;
R d is selected from:
(1) hydrogen,
(2) C 1-10 alkyl, unsubstituted or substituted with one to three substituents selected from R h ,
(3) C 2-4 alkenyl;
(4) cycloalkyl, unsubstituted or substituted with one to three substituents selected from R h ;
(5) cycloalkyl-C 1-4 alkyl;
(6) cycloheteroalkyl, unsubstituted or substituted with one to three substituents selected from R h ;
(7) cycloheteroalkyl-C 1-4 alkyl, unsubstituted or substituted with a R h substituent;
(8) aryl, unsubstituted or substituted with one to three substituents selected from R h ;
(9) heteroaryl, unsubstituted or substituted with one to three substituents selected from R h ;
(10) aryl-C 1-4 alkyl, unsubstituted or substituted with one to three substituents selected from R h ; and
(11) heteroaryl-C 1-4 alkyl, unsubstituted or substituted with one to three substituents selected from R h ;
R e is hydrogen, or
R d and R e together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0 or 1 additional heteroatoms independently selected from oxygen, sulfur and N—R h , unsubstituted or substituted with one or two oxo groups;
R f and R g are independently selected from
(1) hydrogen, and
(2) methyl;
each R h is independently selected from:
(1) halogen,
(2) amino,
(3) hydroxycarbonyl,
(4) C 1-4 alkyl,
(5) C 1-4 alkoxy,
(6) aryl,
(7) aryl C 1-4 alkyl,
(8) hydroxy,
(9) trifluoromethyl,
(10) —OC(O)C 1-4 alkyl,
(11) aryloxy-,
(12) C 1-4 alkyloxycarbonyl-, and
(13) —C(O)—NH—C 1-4 alkyl;
m is selected from 1 and 2;
n is selected from 1, 2, and 3;
p is selected from 0, 1, and 2; and
and pharmaceutically acceptable salts thereof.
7. The compound according to claim 6 , wherein:
R 1 is selected from:
(1) hydrogen,
(2) chloro,
(3) cycloheteroalkyl, selected from piperidyl, piperazinyl, and perhydroazepine,
(4) heteroaryl, selected from imidazole, triazole, benzimidazole,
(5) benzyl,
(6) —Or d ,
(7) —SR d ,
(8) —O—(CH 2 ) 2 —Nr d R e ,
(9) —O—(CH 2 ) 2 —NH—C(O)—R d ,
(10) —O—(CH 2 ) 2 —NH—S(O) p R d ,
(12) —O—(CH 2 ) n —C(O)—Nr d R e ,
(13) —Nr d R e , wherein R e is hydrogen,
(14) —CO 2 H,
(15) —C(O)Nr d R e ,
wherein the cycloheteroalkyl, aryl and heteroaryl are optionally substituted with one to three substituents independently selected from R b ;
R 2 is selected from:
(1) hydrogen,
(2) cyano,
(3) —C(O)OH,
(4) —C(O)OCH 3 ,
(5) —C(O)Nr d R e ,
(6) halogen,
(7) nitro, and
(8) C(O)NH—Nr d R e , wherein R e is hydrogen;
provided that R 1 and R 2 are not both hydrogen;
R 4 , R 6 and R 7 are each independently selected from:
(1) hydrogen,
(2) halogen,
(3) amino,
(4) carboxy,
(5) methyl,
(6) and
(7) trifluoromethyl;
provided that R 6 and R 7 are not both hydrogen;
each R b is independently selected from:
(1) halogen,
(2) —CF 3 ,
(3) cyclopropyl, and
(4) methyl;
R d is selected from:
(1) hydrogen,
(2) C 1-10 alkyl;
(3) C 2-4 alkenyl;
(4) cycloalkyl;
(5) cycloalkyl-C 1-4 alkyl;
(6) cycloheteroalkyl, unsubstituted or substituted with one to three substituents selected from R h ;
(7) cycloheteroalkyl-C 1-4 alkyl, unsubstituted or substitute with a R h substituent;
(8) aryl, unsubstituted or substituted with one to three substituents selected from R h ;
(9) heteroaryl, unsubstituted or substituted with one to three substituents selected from R h ;
(10) aryl-C 1-4 alkyl, unsubstituted or substituted with one to two substituents selected from R h ; and
(11) heteroaryl-C 1-4 alkyl, unsubstituted or substituted with one to three substituents selected from R h ;
R e is hydrogen, or
R d and R e together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0 or 1 additional heteroatoms independently selected from oxygen, sulfur and N—R h , unsubstituted or substituted with one or two oxo groups;
each R h is independently selected from:
(1) halogen,
(2) amino,
(3) hydroxycarbonyl,
(4) methyl,
(5) methoxy-,
(6) phenyl,
(7) benzyl,
(8) hydroxy,
(9) trifluoromethyl,
(10) methylcarbonyloxy-,
(11) C 1-4 alkyloxycarbonyl-, and
(12) —C(O)—NH—C 1-4 alkyl;
m is selected from 1 and 2;
n is selected from 1, 2, and 3;
p is selected from 0, 1, and 2; and
and pharmaceutically acceptable salts thereof.
8. The compound according to claim 5 , selected from:
(1) 2-(benzyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)nicotinonitrile,
(2) 2-chloro-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-N-hexylnicotinamide,
(3) 2-chloro-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-N-propylnicotinamide,
(4) 2-(benzyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-N-methylnicotinamide,
(5) 2-(benzyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-N,N-dimethylnicotinamide,
(6) 2-(benzyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-N-propylnicotinamide,
(7) 2-(benzyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-N-pentylnicotinamide,
(8) 2-(benzyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-N-piperidin-1-ylnicotinamide,
(9) 2-(benzyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)nicotinamide,
(10) methyl2-(benzyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)nicotinate,
(11) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-N-hexylnicotinamide,
(12) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(4-fluorobenzyl)oxy]nicotinonitrile,
(13) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(2,4-difluorobenzyl)oxy]nicotinonitrile,
(14) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorobenzyl)oxy]nicotinonitrile,
(15) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-{[4-trifluoromethyl)benzyl]oxy}nicotinonitrile,
(16) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,5-difluorobenzyl)oxy]nicotinonitrile,
(17) methyl 5-(4-chlorophenyl)-2-(cyclohexylmethoxy)-6-(2,4-dichlorophenyl)nicotinate,
(18) methyl 5-(4-chlorophenyl)-2-(cyclopropylmethoxy)-6-(2,4-dichlorophenyl)nicotinate,
(19) methyl 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(pentyloxy)nicotinate,
(20) 2-(benzyloxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-N-ethylnicotinamide,
(21) 2-(benzyloxy)-N-butyl-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)nicotinamide,
(22) 2-(benzyloxy)-5-(4-chlorophenyl)-N-cyclopentyl-6-(2,4-dichlorophenyl)nicotinamide,
(23) methyl 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(2-ethoxyethoxy)nicotinate,
(24) 5-(4-chlorophenyl)-2-(cyclohexylmethoxy)-6-(2,4-dichlorophenyl)-N-methylnicotinamide,
(25) 2-butoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)nicotinamide,
(26) 2-butoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-N-methylnicotinamide,
(27) 2-butoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-N-propylnicotinamide,
(28) 2-butoxy-5-(4-chlorophenyl)-N-cyclopentyl-6-(2,4-dichlorophenyl)nicotinamide,
(29) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorobenzyl)oxy]-N-ethylnicotinamide,
(30) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorobenzyl)oxy]-N-propylnicotinamide,
(31) 5-(4-chlorophenyl)-N-cyclohexyl-6-(2,4-dichlorophenyl)pyridine-2-carboxamide,
(32) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorobenzyl)oxy]-N-methylnicotinamide,
(33) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorobenzyl)oxy]-N-(2-fluoroethyl)nicotinamide,
(34) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorobenzyl)oxy]-N-isopropylnicotinamide,
(35) methyl5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorobenzyl)oxy]nicotinate,
(36) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-N-piperidin-1-ylpyridine-2-carboxamide,
(37) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-N-hexylpyridine-2-carboxamide,
(38) 5-(4-chlorophenyl)-N-cyclopentyl-6-(2,4-dichlorophenyl)pyridine-2-carboxamide,
(39) 5-(4-chlorophenyl)-N-cycloheptyl-6-(2,4-dichlorophenyl)pyridine-2-carboxamide,
(40) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-N-( 1 -propylbutyl)pyridine-2-carboxamide,
(41) N-benzyl-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyridine-2-carboxamide,
(42) 5,6-bis(2,4-dichlorophenyl)-2-[(3,4-difluorobenzyl)oxy]nicotinonitrile,
(43) 6-(2,4-dichlorophenyl)-5-(3,4-dichlorophenyl)-2-[(3,4-difluorobenzyl)oxy]nicotinonitrile,
(44) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[1-(4-fluorophenyl)ethoxy]nicotinonitrile,
(45) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)nicotinonitrile,
(46) 2-(1,3-benzodioxol-5-ylmethoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)nicotinonitrile,
(47) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(2-methoxyethoxy)nicotinonitrile,
(48) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3-fluorophenoxy)nicotinonitrile,
(49) 5-(4-chlorophenyl)-2-(cyclohexyloxy)-6-(2,4-dichlorophenyl)nicotinonitrile,
(50) 2-(4-chlorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)nicotinonitrile,
(51) 2-(3-chlorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)nicotinonitrile,
(52) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(4-methoxyphenoxy)nicotinonitrile,
(53) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(pyridin-3-yloxy)nicotinonitrile,
(54) 2-[(3-chlorobenzyl)oxy]-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)nicotinonitrile,
(55) 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-6-[(3,4-difluorobenzyl)oxy]pyridine,
(56) 5-(4-chlorophenyl)-2-[(5-chloropyridin-3-yl)oxy]-6-(2,4-dichlorophenyl)nicotinonitrile,
(57) methyl5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)nicotinate,
(58) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-N-methylnicotinamide,
(59) 5-(4-chlorophenyl)-N-cyclohexyl-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)nicotinamide,
(60) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-N-pyrrolidin-1-ylnicotinamide,
(61) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-N′,N′-dimethylnicotinohydrazide,
(62) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-N-ethylnicotinamide,
(63) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)-N-isopropylnicotinamide,
(64) methyl5-(4-chlorophenyl)-2-[(5-chloropyridin-3-yl)oxy]-6-(2,4-dichlorophenyl)nicotinate,
(65) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)nicotinamide,
(66) N-(2-{[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]oxy}ethyl)cyclopropanecarboxamide,
(67) N-(2-{[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]oxy}ethyl)cyclobutanecarboxamide,
(68) N-(2-{[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]oxy}ethyl)cyclopentanecarboxamide,
(69) N-(2-{[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]oxy}ethyl)benzamide,
(70) N-(2-{[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]oxy}ethyl)-4-fluorobenzamide,
(71) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(pyridin-2-yloxy)nicotinonitrile,
(72) 5-(4-chlorophenyl)-3-cyano-N-cyclohexyl-6-(2,4-dichlorophenyl)pyridine-2-carboxamide,
(73) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3 ,5-difluorophenoxy)nicotinonitrile,
(74) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)nicotinonitrile,
(75) [5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)pyridin-3-yl]methanol,
(76) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)nicotinonitrile,
(77) 5-(4-chlorophenyl)-3-cyano-N-cyclopentyl-6-(2,4-dichlorophenyl)pyridine-2-carboxamide,
(78) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(4,4-dimethyl-2-oxo-1,3-oxazolidin-3-yl)nicotinonitrile,
(79) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(tetrahydro-2H-pyran-2-ylmethoxy)nicotinonitrile,
(80) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-isopropoxynicotinonitrile,
(81) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-ethoxynicotinonitrile,
(82) N-[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]benzamide,
(83) N-benzoyl-N-[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]benzamide,
(84) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(tetrahydrofuran-3-yloxy)nicotinonitrile,
(85) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(tetrahydrofuran-3-ylmethoxy)nicotinonitrile,
(86) 2-(1H-1,2,3-benzotriazol-1-yl)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)nicotinonitrile,
(87) N-[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]-3,4-difluorobenzamide,
(88) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(piperidin-1-yloxy)nicotinonitrile,
(89) N-[5-(4-chlorophenyl)-3-cyano-6-(2,4-dichlorophenyl)pyridin-2-yl]-2,2-dimethyipropanamide,
(90) methyl2-(3-chlorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)nicotinate,
(91) 2-(3-chlorophenoxy)-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-N′,N′-dimethylnicotinohydrazide, (92) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(1H-1,2,3-triazol-1-yl)nicotinonitrile, (93) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-[(3,4-difluorobenzyl)oxy]-N′,N′-dimethylnicotinohydrazide,
(94) methyl2-butoxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)nicotinate,
(95) 5-(4-chlorophenyl)-2-(cyclohexylmethoxy)-6-(2,4-dichlorophenyl)-N-propylnicotinamide,
(96) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(4-fluorophenoxy)nicotinonitrile,
(97) 5-(4-chlorophenyl)-2-(3,5-dichlorophenoxy)-6-(2,4-dichlorophenyl)nicotinonitrile,
(98) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorobenzyl)nicotinonitrile,
(99) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenoxy)nicotinamide,
(100) 5′-(4-chlorophenyl)-6′-(2,4-dichlorophenyl)-2-oxo-2H-1,2′-bipyridine-3-carbonitrile,
(101) 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(isopropylamino)nicotinonitrile,
and pharmacuetically acceptable salts thereof.